WASHINGTON, April 28 -- The Congressional Research Service issued the following report (No. R48179) on April 21, 2025, entitled "Coast Guard Polar Security Cutter and Arctic Security Cutter Icebreaker Programs - Background and Issues for Congress:" (Continued from Part 1 of 3) * * * Arctic Security Cutter (ASC) Program Overview As mentioned earlier, the Coast Guard refers to its planned new medium polar icebreakers as Arctic Security Cutters (ASCs). April 2025 Request for Information (RFI  more

NEW YORK, April 29 (TNSres) -- The Memorial Sloan Kettering Cancer Center issued the following news release: * * * Immunotherapy Could Replace Surgery, Enabling Patients To Retain Their Organs and Enhance Their Quality of Life CHICAGO -- New results from a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK), gastrointestinal oncologists Andrea Cercek, MD, and Luis Diaz Jr., MD, demonstrate how immunotherapy alone can allow people with MMRd cancers to avoid surgery and preserve  more

ST. LOUIS PARK, Minnesota, April 28 [Category: Medical] -- Medical Alley posted the following news release: * * * In the Know: Healthcare News for April 28, 2025 Opinion: Minnesota's Medicaid benefits extend beyond patients HistoSonics' Histotripsy System Demonstrates 90% Local Tumor Control at 12 Months in #HOPE4LIVER Trials Medtronic inks new distro agreement for Retia Medical Argos cardiac output monitor Abbott Highlights New AVEIR(tm) Data, Initiates Trial for the Company's Conducti  more

CANTON, Ohio, April 28 [Category: Sports] -- The National Football League posted the following news: * * * NFL Power Rankings: 49ers, Chiefs, Cowboys among 18 movers after 2025 draft From No. 1 overall pick Cam Ward to "Mr. Irrelevant" Kobee Minor (fittingly, a player I hadn't studied pre-draft), the 2025 NFL Draft is now a memory. The three-day event almost immediately provided fireworks with the fascinating Travis Hunter trade, and the Shedeur Sanders drama lingered well into Saturday. It  more

PHILADELPHIA, Pennsylvania, April 28 [Category: Medical] -- The American Association for Cancer Research posted the following news release: * * * Oral HER2-targeted Therapy Zongertinib Demonstrates Clinical Benefit in Advanced HER2-mutated Lung Cancer CHICAGO - Zongertinib, a human epidermal growth factor receptor 2 (HER2)-targeted tyrosine kinase inhibitor, elicited durable responses in patients with advanced, previously treated non-small cell lung cancer (NSCLC) that harbored a HER2 mutatio  more

HOUSTON, Texas, April 28 -- The University of Texas MD Anderson Cancer Center issued the following news release: * * * AACR: HER2 targeted therapy shows promise in previously treated lung cancers Oral therapy is under priority review by the FDA * Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer. * These cancers are associated with resistance to standard therapies and a very poor prognosis. * As an oral pill, zonge  more